Disease Landscape and Forecast Insights

In the past decade, the TNF-α inhibitors Humira (AbbVie) and Enbrel (Amgen) and the IL-12/23 inhibitor Stelara (Janssen) have been leading the U.S. psoriasis biologics market. However, the recent…

MARKET OUTLOOK The treatment landscape for psoriasis in the top 5 European markets (France, Germany, Italy, Spain, UK) is extremely dynamic. Humira (AbbVie), Enbrel (Amgen), Stelara (Janssen), and…

With a drug-treated population of more than 4 million people in the United States and EU5, the psoriasis market has been a lucrative space for drug developers, resulting in a plethora of approved…

MARKET OUTLOOK Despite similarities between adult psoriasis and pediatric psoriasis, pediatric psoriasis presents a challenge for patients seeking effective long-term therapy. Thetreatments…

MARKET OUTLOOK Increasingly, moderate-to-severe psoriasis represents an increasingly lucrative market for targeted systemic treatments. Although adult psoriasis and pediatric psoriasis are…

The psoriasis therapy market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12/23…

In the past decade, TNF-α inhibitors Humira (AbbVie) and Enbrel (Amgen), as well as Janssen’s IL-12/23 inhibitor Stelara, have been leading the U.S. psoriasis biologics market. However, the…

The psoriasis market has become increasingly lucrative owing to the growing use of biologics in the moderate to severe patient population, who cannot be adequately controlled with topical agents…

MARKET OUTLOOK Psoriasis Current Treatment: Physician Insights probes the current and future use of topical agents, phototherapy, and systemic therapies in the treatment of mild, moderate, and…

IL-17 inhibitors have set a new efficacy standard in moderate to severe psoriasis, putting pressure on the more established TNF-α inhibitors and the IL-12/23 inhibitor Stelara. Although IL-17…

In the past decade, TNF-α inhibitors Humira (AbbVie) and Enbrel (Amgen), as well as IL-12/23 inhibitor Stelara (Janssen), have been leading the U.S. psoriasis biologics market. However, the…

IL -17 inhibitors have established a high standard for efficacy in moderate to severe psoriasis, placing pressure on current therapies that are less efficacious and a great number of…